These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6388898)

  • 1. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.
    Collen D; Topol EJ; Tiefenbrunn AJ; Gold HK; Weisfeldt ML; Sobel BE; Leinbach RC; Brinker JA; Ludbrook PA; Yasuda I
    Circulation; 1984 Dec; 70(6):1012-7. PubMed ID: 6388898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.
    Flameng W; Van de Werf F; Vanhaecke J; Verstraete M; Collen D
    J Clin Invest; 1985 Jan; 75(1):84-90. PubMed ID: 4038406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
    Gold HK; Fallon JT; Yasuda T; Leinbach RC; Khaw BA; Newell JB; Guerrero JL; Vislosky FM; Hoyng CF; Grossbard E
    Circulation; 1984 Oct; 70(4):700-7. PubMed ID: 6541103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
    J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
    Van de Werf F; Vanhaecke J; de Geest H; Verstraete M; Collen D
    Circulation; 1986 Nov; 74(5):1066-70. PubMed ID: 2429783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolysis with recombinant tissue plasminogen activator in atherosclerotic thrombotic occlusion.
    Topol EJ; Ciuffo AA; Pearson TA; Dillman J; Builder S; Grossbard E; Weisfeldt ML; Bulkley BH
    J Am Coll Cardiol; 1985 Jan; 5(1):85-91. PubMed ID: 4038373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.
    Van de Werf F; Ludbrook PA; Bergmann SR; Tiefenbrunn AJ; Fox KA; de Geest H; Verstraete M; Collen D; Sobel BE
    N Engl J Med; 1984 Mar; 310(10):609-13. PubMed ID: 6537987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    J Am Coll Cardiol; 1988 Sep; 12(3):581-7. PubMed ID: 3042835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled trial of tissue plasminogen activator in unstable angina.
    Nicklas JM; Topol EJ; Kander N; O'Neill WW; Walton JA; Ellis SG; Gorman L; Pitt B
    J Am Coll Cardiol; 1989 Feb; 13(2):434-41. PubMed ID: 2492325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.
    Verstraete M; Bernard R; Bory M; Brower RW; Collen D; de Bono DP; Erbel R; Huhmann W; Lennane RJ; Lubsen J
    Lancet; 1985 Apr; 1(8433):842-7. PubMed ID: 2858711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.
    Mueller HS; Rao AK; Forman SA
    J Am Coll Cardiol; 1987 Sep; 10(3):479-90. PubMed ID: 3114349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
    Flameng W; Vanhaecke J; Stump DC; Van de Werf F; Holmes W; Guenzler WA; Flohe L; Collen D
    J Am Coll Cardiol; 1986 Jul; 8(1):118-24. PubMed ID: 3086416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris.
    Gold HK; Johns JA; Leinbach RC; Yasuda T; Grossbard E; Zusman R; Collen D
    Circulation; 1987 Jun; 75(6):1192-9. PubMed ID: 3105913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction.
    Rogers WJ; Mantle JA; Hood WP; Baxley WA; Whitlow PL; Reeves RC; Soto B
    Circulation; 1983 Nov; 68(5):1051-61. PubMed ID: 6352081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
    Johns JA; Gold HK; Leinbach RC; Yasuda T; Gimple LW; Werner W; Finkelstein D; Newell J; Ziskind AA; Collen D
    Circulation; 1988 Sep; 78(3):546-56. PubMed ID: 3136953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
    Rao AK; Pratt C; Berke A; Jaffe A; Ockene I; Schreiber TL; Bell WR; Knatterud G; Robertson TL; Terrin ML
    J Am Coll Cardiol; 1988 Jan; 11(1):1-11. PubMed ID: 3121710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.